{"id":898878,"date":"2025-10-22T09:35:05","date_gmt":"2025-10-22T13:35:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/"},"modified":"2025-10-22T09:35:05","modified_gmt":"2025-10-22T13:35:05","slug":"hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/","title":{"rendered":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cMVIitldAvRbb2vJTMzXmlSLPhxRNZf6Ob0CXvvNi-PkvmTSC8JPy8vIb67k11kPGAIPndiqRlgEo8AxTOF6tHpS__7o8G6SQsMUCblFI6m14jVasYBhysX39Wo5ohpkhVk2oL3aTHujNFA2ljZ8dA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>Watch the &#8220;What This Means&#8221; video here<\/em><br \/>\n          <\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"center\">\n        <em>Featuring the Company\u2019s pembrolizumab-based immune checkpoint inhibitor <\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>MIRAMAR, Fla., Oct.  22, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-tu0PKtyDMwk4yRh6krM0HEYpwDKVvfJatZU6g3W6iJeo56nwHc-8lAY8ZgDzklc95wCn6AMYZ_tOiE79FMzaCryp7buWLwGszxPZqqNl-2Cfgtkq4Zb5v5v_00L65BV4Wrhe2V_CHarvIqCMjBh03sI4EYNt1ujOo9RcCJTQ75QrKByKOVwf_eYHihJp0ac1wtir0VERMNjdGKgfrEciA==\" rel=\"nofollow\" target=\"_blank\">Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations<\/a> of HCW Biologics, participated in a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Dpan8KcK0nPRWmJqacjToroWWGp4Fzkz_Xzkmage0GOrG5o-TuIS1lewhHIKS8IBn21jZ9t7xw6RwDGZDTc4r6I9JiChBtJr9HxZLVbEp295tdsuXznmjYzmj8pndW7N55N2rjlTgACs_rkV_Y4gow==\" rel=\"nofollow\" target=\"_blank\">Virtual Investor \u201cWhat This Means\u201d segment<\/a>.<\/p>\n<p align=\"justify\">Dr. Rhode\u2019s presentation features the Company\u2019s lead product candidate, known as HCW11-040, which is the Company\u2019s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor. HCW11-040 is a multi-functional fusion protein constructed using the Company\u2019s novel drug discovery and development platform, called the TRBC platform. This compound is a unique combination of pembrolizumab, commonly known as Keytruda<sup>\u00ae<\/sup> (a registered trademark of Merck Sharp &amp; Dohme LLC), along with interleukin-7, interleukin-15, and TGF-\u03b2 receptor components (TGF-\u03b2 traps). The Company has discovered through preclinical testing that this unique combination exhibits the ability to expand the exhausted T cells or TPEX cells without causing side effects. TPEX cells are located in the lymph nodes near the cancer site and these cells have been implicated as the primary responders to immune checkpoint inhibitor therapy. TPEX cells have stem cell-like properties and can change into effector T cells for providing anti-tumor effects. To improve the activity of immune checkpoint inhibitors, the Company added cytokine components that further expand and activate these TPEX cells.\u00a0\u00a0 The efficacy of immune checkpoint inhibitors can be further improved by equipping them with other moieties such as TGF-\u03b2 traps that neutralize immunosuppressive factors, particularly one called TGF-\u03b2.<\/p>\n<p align=\"justify\">At the upcoming 40<sup>th<\/sup> annual meeting of the Society for Immunotherapy of Cancer (\u201cSITC\u201d), the Company will be presenting extensive data for HCW11-040 in a poster presentation entitled, \u201cA novel tetra-specific pembrolizumab-based immunotherapeutic,\u201d that will be available at SITC on November 8, 2025.<\/p>\n<p align=\"justify\">The Virtual Investor \u201cWhat This Means\u201d segment featuring HCW Biologics is now available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pM0T16WZME1bsMEAy_zKsOcdOZrrXlnfQpGXzoKt8-I22i8e3aYtDOi6WDpftveMogMvbDF7IOZndkKjeqLkeJO5NqQr9bCmfyyIoElQ7JM=\" rel=\"nofollow\" target=\"_blank\">here<\/a>. <\/p>\n<p align=\"justify\">\n        <strong>About HCW Biologics:<\/strong>\n      <\/p>\n<p align=\"justify\">HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company\u2019s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation \u2014 and in doing so, improve patients\u2019 quality of life and potentially extend longevity.\u00a0Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening.\u00a0The Company\u2019s lead product candidate, HCW9302, was developed using the Company\u2019s legacy\u00a0TOBI\u2122\u00a0(Tissue factOr-Based fusIon)\u00a0platform. The Company has created another drug discovery technology,\u00a0the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-040. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data.\u00a0The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hmHYmA_WRiDmI94ALaeRlaStRlYA7oww1IjikwDXNsmFbzo6vPe2evIenNl3LV12jCQzGiGWV9EtiIFYNKHgA2wGs2Any_jDz-t-vc0zbeNvtncfOEMJ8OP2jtpdChqnWU_KacWnwDXeIQ90bcrmfsFLKo5CaIqkq0uL6WhqYrWCSespiM81QdZO9dW246dgQSw6835DEP0px3j2O7MjlG-4YgQ6PjTj35keEdJwxkQ7NXxxO5LjEPOoPY-iiRxE85YvXg-KSaE36zpVikfJ0vBIC0nsh_ZmqWizdPNYJ9gdJ_rnP0V2EdVGor1UFsOU\" rel=\"nofollow\" target=\"_blank\">https:\/\/hcwbiologics.com\/pipeline\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements:<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast\u201d or other similar words and include, the actual success and potency of pembrolizumab-based TRBC fusion molecules; whether pembrolizumab-based TRBC fusion molecules will exhibit potent anti-pancreatic cancer activities and continue to outperform pembrolizumab both <em>in vitro<\/em> and in humanized mouse models; or whether pembrolizumab-based TRBC fusion molecules are effective in treatment of solid tumors and pancreatic cancers. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled \u201cRisk Factors\u201d in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the \u201cSEC\u201d) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Dr. Peter Rhode<\/strong><br \/>\n        <br \/>Chief Scientific Officer and Vice President of Clinical Operations<br \/>HCW Biologics Inc.<br \/>PeterRhode@HCWBiologics.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2YwMTc3YTMtZDExOS00MjhmLWE2MDQtY2Q4MDI1YzQzNjdhLTEyMjE3NTEtMjAyNS0xMC0yMi1lbg==\/tiny\/HCW-Biologics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Watch the &#8220;What This Means&#8221; video here Featuring the Company\u2019s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor \u201cWhat This Means\u201d segment. Dr. Rhode\u2019s presentation features the Company\u2019s lead product candidate, known as HCW11-040, which is the Company\u2019s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor. HCW11-040 is a multi-functional fusion protein constructed using the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898878","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Watch the &#8220;What This Means&#8221; video here Featuring the Company\u2019s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor \u201cWhat This Means\u201d segment. Dr. Rhode\u2019s presentation features the Company\u2019s lead product candidate, known as HCW11-040, which is the Company\u2019s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor. HCW11-040 is a multi-functional fusion protein constructed using the &hellip; Continue reading &quot;HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T13:35:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment\",\"datePublished\":\"2025-10-22T13:35:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/\"},\"wordCount\":901,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/\",\"name\":\"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=\",\"datePublished\":\"2025-10-22T13:35:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/","og_locale":"en_US","og_type":"article","og_title":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk","og_description":"Watch the &#8220;What This Means&#8221; video here Featuring the Company\u2019s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor \u201cWhat This Means\u201d segment. Dr. Rhode\u2019s presentation features the Company\u2019s lead product candidate, known as HCW11-040, which is the Company\u2019s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor. HCW11-040 is a multi-functional fusion protein constructed using the &hellip; Continue reading \"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T13:35:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment","datePublished":"2025-10-22T13:35:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/"},"wordCount":901,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/","name":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=","datePublished":"2025-10-22T13:35:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTc4MSM3MjA4MTY5IzIyMTAxOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-inc-nasdaq-hcwb-participates-in-virtual-investor-what-this-means-segment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor \u201cWhat This Means\u201d Segment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898878"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898878\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}